Especially, these finding provide insights into why not all RAS/RAF WT CRC patients benefit from cetuximab treatment (only about 50% of the patients respond well).61 These results highlighted that the status of other factors needs to be considered, such as CSN6 and FASN levels, before the administration of cetuximab. Here, FASN is linked to colorectal carcinoma.